Scarica l'app Stockscreener
0.00
100.00%
-131.87
Precedente Chiudi:
$131.87
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$14.05B
Reddito:
$612.78M
Utile/perdita netta:
$-86.37M
Rapporto P/E:
0.00
EPS:
-0.87
Flusso di cassa netto:
$-62.91M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$131.98
Intra Cellular Therapies Inc Stock (ITCI) Company Profile
Nome
Intra Cellular Therapies Inc
Settore
Telefono
(646) 440-9333
Indirizzo
135 ROUTE 202/206, BEDMINSTER, NY
Confronta ITCI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ITCI
Intra Cellular Therapies Inc
|
0.00 | 14.05B | 612.78M | -86.37M | -62.91M | -0.87 |
|
ZTS
Zoetis Inc
|
148.67 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.22 | 45.62B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.71 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.65 | 15.60B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.73 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-24 | Downgrade | Mizuho | Outperform → Neutral |
| 2025-01-31 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2024-09-06 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-12-11 | Iniziato | TD Cowen | Outperform |
| 2023-04-20 | Iniziato | Morgan Stanley | Overweight |
| 2022-08-22 | Downgrade | Goldman | Buy → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-06-14 | Iniziato | UBS | Buy |
| 2022-04-22 | Iniziato | Piper Sandler | Neutral |
| 2022-02-16 | Iniziato | Goldman | Buy |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2020-12-15 | Iniziato | BofA Securities | Buy |
| 2020-12-10 | Iniziato | Goldman | Buy |
| 2020-02-20 | Iniziato | Evercore ISI | Outperform |
| 2020-01-31 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-12-24 | Reiterato | Canaccord Genuity | Buy |
| 2019-08-12 | Iniziato | Jefferies | Buy |
| 2018-02-26 | Iniziato | JP Morgan | Overweight |
| 2018-02-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-12-15 | Iniziato | Canaccord Genuity | Buy |
| 2017-11-08 | Aggiornamento | SunTrust | Hold → Buy |
| 2017-09-07 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2017-08-30 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2017-08-24 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-08-23 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2017-05-02 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2017-05-02 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2017-05-01 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-12-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-09-29 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-09-29 | Downgrade | SunTrust | Buy → Neutral |
Mostra tutto
Intra Cellular Therapies Inc Borsa (ITCI) Ultime notizie
Trend Tracker for (ITCI) - news.stocktradersdaily.com
Zynext Ventures Invests in Feldan Therapeutics to Drive Innovation in Intracellular Drug Delivery - Yahoo Finance
JNJ Tops Q1 Earnings, Ups '25 Sales View to Include Intra-Cellular Deal - TradingView
Johnson & Johnson Reports Q1 2025 Results - BioSpace
Intra-Cellular Therapies’ SWOT analysis: acquisition shifts landscape for psychiatric drug stock - Investing.com Canada
Intra-Cellular Therapies’ SWOT analysis: acquisition shifts landscape for psychiatric drug stock By Investing.com - Investing.com South Africa
Johnson & Johnson - drugdiscoverytrends.com
Johnson & Johnson Expects Lower Earnings Impact From Intra-Cellular Therapies Acquisition - MSN
J&J acquires Intra-Cellular Therapies in multi-billion-dollar deal - ROI-NJ
J&J to complete acquisition of Intra-Cellular Therapies - Medical Buyer
JnJ closes Intra-Cellular Therapies acquisition - Medical Dialogues
JNJ forecasts 2025 profit dilution from Intra-Cellular deal, sets closing date - MSN
Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews - Benzinga
Intra-Cellular Therapies acquired by Johnson & Johnson for $14.6 billion - Investing.com South Africa
Intra-Cellular Therapies Completes Merger with Johnson & Johnson - TipRanks
Johnson & Johnson acquires Intra-Cellular Therapies By Investing.com - Investing.com South Africa
Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended - Benzinga
Johnson & Johnson Acquires Intra-Cellular Therapies - citybiz
Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership - BioSpace
Johnson & Johnson Completes Intra-Cellular Therapies Purchase - MarketScreener
JNJ Completes Acquisition Of Intra-Cellular Therapies - Nasdaq
Johnson & Johnson acquires Intra-Cellular Therapies - Investing.com
Johnson & Johnson completes Intra-Cellular Therapies acquisition, sees dilution - TipRanks
Johnson & Johnson (JNJ) Closes Intra-Cellular Therapies, Inc. (ITCI) Acquisition - StreetInsider
Johnson & Johnson Expands Its Horizon With Intra-Cellular Therapies Deal - Finimize
Johnson & Johnson Set To Complete Acquisition Of Intra-Cellular Therapies By April 2, 2025 - Nasdaq
Johnson & Johnson to finalize Intra-Cellular buyout By Investing.com - Investing.com Canada
Johnson & Johnson to finalize Intra-Cellular buyout - Investing.com
Johnson & Johnson Intra-Cellular acquisition to accelerate FY25 sales by 0.8% - TipRanks
Johnson & Johnson (JNJ) Sets April 2nd as Expected Closing Date for Intra-Cellular Acquisition - StreetInsider
Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition - The Joplin Globe
Intra-cellular Therapeutics Surges to 322nd in Trading Volume Ranking with 3.36 Billion Shares Exchanged - AInvest
(ITCI) On The My Stocks Page - news.stocktradersdaily.com
Intra-cellular Therapies Surges to 340th in Daily Rankings with 2.46 Billion Turnover - AInvest
Intra-Cellular Therapies Stock Hits All-Time High of $131.79 By Investing.com - Investing.com South Africa
Intra-Cellular Therapies Shareholders Approve Johnson & Johnson Merger - Investing.com
Intra-Cellular Therapies Shareholders Approve Johnson & Johnson Merger By Investing.com - Investing.com Australia
Beam Therapeutics (BEAM) Down 21.4% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Intra-Cellular Therapies Stock Hits All-Time High of $131.79 - Investing.com
Intra-Cellular Therapies: These Are 5 Critical Challenges Threatening Its Expansion Plans! - Smartkarma
Intra-Cellular Therapies announces proxy statement supplement By Investing.com - Investing.com South Africa
Intra-Cellular Therapies announces proxy statement supplement - Investing.com
Intra-Cellular Therapies stockholder filed lawsuit against co, board in NY Supreme Court - Marketscreener.com
Intra-Cellular Therapies Stock Hits All-Time High of $131.47 By Investing.com - Investing.com UK
Intra-Cellular Therapies (ITCI): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance
US Bancorp DE Sells 4,330 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Defense World
Scrip M&A Podcast: Looking At M&A Activity As Q1 Nears A Close - Scrip
Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by StockNews.com - Defense World
Intra-Cellular Therapies Stock Hits All-Time High of $131.37 By Investing.com - Investing.com Australia
Intra-Cellular Therapies Stock Hits All-Time High of $131.37 - Investing.com
Jones Financial Companies Lllp Acquires 2,750 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Defense World
Intra Cellular Therapies Inc Azioni (ITCI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.16%
1.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):